Welcome to our dedicated page for Cadrenal Therape SEC filings (Ticker: CVKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Cadrenal Therapeutics, Inc. Chairman, CEO and Interim CFO Quang X Pham reported open-market sales of a total of 22,385 shares of common stock over three days. Shares were sold at weighted average prices of about $4.38 on June 8, $4.06 on June 9, and $4.21 on June 10, in transactions described as carried out under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these sales, Pham holds 150,839 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang X. Pham reported open-market sales of a total of 8,285 shares of common stock on June 3–5, 2026 at weighted average prices of $4.26, $4.41 and $4.42 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the transactions, he holds 173,224 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. reported that Chief Financial Officer Matthew K. Szot mutually agreed to transition out of his role effective May 28, 2026. Immediately afterward, the company appointed Chief Executive Officer Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer while it conducts a search for a permanent CFO.
Under a Severance Agreement dated June 3, 2026, Mr. Szot is entitled to a cash severance of $365,806.00 paid in four installments and his fiscal 2026 target cash bonus of $237,903.00 paid in two installments, all subject to standard deductions and withholdings. All of his outstanding stock options will fully vest and remain exercisable until their original expiration dates. The agreement includes a seven-day Revocation Period, a general release of claims, and a non-disparagement clause.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang Pham reported small open-market sales of company common stock. He sold 303 shares on May 29, 2026 at a weighted average price of $5.01 per share and 349 shares on June 2, 2026 at a weighted average price of $4.46 per share, totaling 652 shares. The sales were executed under a pre-arranged Rule 10b5-1 trading arrangement. After these transactions, Pham holds 181,509 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang X Pham reported open-market sales of 12,763 shares of common stock. The sales occurred on May 11, May 12, and May 28, 2026, at reported weighted average prices of $5.76, $5.28, and $4.93 per share.
The footnotes state these transactions were made under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the latest sale, Pham holds 182,161 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power. The filing also corrects an earlier understatement of indirect holdings on a prior Form 4.
Cadrenal Therapeutics CEO and Chairman Quang Pham reported an open-market sale of 1,165 shares of Common Stock on May 22, 2026 at a weighted average price of $5.69 per share, executed as an "S" code transaction.
The sale was made pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025, meaning it was pre-arranged. After the sale, Pham directly owns 194,924 shares of Cadrenal Therapeutics common stock and indirectly holds 20,000 shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power.
Cadrenal Therapeutics reported first quarter 2026 results and outlined next steps for its lead drug CAD-1005 in heparin-induced thrombocytopenia (HIT). Operating expenses fell to $2.5 million from $3.9 million a year earlier, narrowing the net loss to $2.5 million from $3.8 million.
As of March 31, 2026, the company held $2.3 million in cash and cash equivalents and later completed a $2.5 million financing to support near-term development. After receiving official End-of-Phase 2 FDA meeting minutes, Cadrenal plans a randomized, blinded, placebo-controlled Phase 3 registration trial of CAD-1005 added to standard care in HIT.
Cadrenal Therapeutics reported a Q1 2026 net loss of $2.5 million, narrower than $3.8 million a year earlier, as operating expenses fell 36% to $2.5 million. Cash and cash equivalents were $2.3 million with net cash used in operations of $3.0 million, raising substantial doubt about its ability to continue as a going concern.
The late-stage biopharma is prioritizing lead candidate CAD-1005 for heparin-induced thrombocytopenia and plans a Phase 3 trial targeting an NDA submission in 2029. Stockholders’ equity of $1.8 million fell below Nasdaq’s $2.5 million requirement, though a subsequent $2.5 million warrant exercise in April 2026 is expected to bolster equity.
Cadrenal Therapeutics announced that it successfully completed its End-of-Phase 2 meeting with the FDA and received guidance for a pivotal Phase 3 trial of CAD-1005 in heparin-induced thrombocytopenia (HIT). Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy.
The company plans a randomized, blinded, placebo-controlled Phase 3 study in approximately 120 HIT patients across up to 50 clinical centers worldwide, with treatment for up to 14 days during hospitalization. The trial is intended to support a projected NDA submission in 2029.